Mega%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv

# Mega-cv ## Overview Mega-cv is a combination product containing Ascorbic Acid (Vitamin C) and Phytonadione (Vitamin K1). ## Primary Indications Mega-cv is indicated for the prevention and treatment of Vitamin K deficiency. It is also used for the prevention of hemorrhagic disease of the newborn. ## Adult Dosing * **Prevention of Vitamin K Deficiency:** 1 mg to 2 mg subcutaneously or intramuscularly once. * **Treatment of Vitamin K Deficiency:** Varies based on severity and indication. Oral or intravenous administration may be used. Dosing is typically 1 mg to 25 mg once or daily, potentially with repeat doses. Specific protocols should be followed. * **Hemorrhagic Disease of the Newborn (Prevention):** 0.5 mg to 1 mg intramuscularly within 1 hour of birth. A second dose may be given at 6-7 days of age and a third dose at 1 month of age. ## Pediatric Dosing * **Hemorrhagic Disease of the Newborn (Prevention):** 0.5 mg to 1 mg intramuscularly within 1 hour of birth. A second dose may be given at 6-7 days of age and a third dose at 1 month of age. ## Dose Adjustments * **Renal Impairment:** No specific dose adjustments are typically required for Vitamin K1. Ascorbic acid dose may need adjustment in severe renal impairment to avoid hyperoxaluria. * **Hepatic Impairment:** No specific dose adjustments are typically required for Vitamin K1. Ascorbic acid dose may need adjustment in severe hepatic impairment. ## Contraindications * Hypersensitivity to any component of the formulation. * Severe liver disease (caution advised for Vitamin K1, as it may be less effective). ## Adverse Effects * **Common:** Pain, swelling, or redness at the injection site. * **Rare:** Allergic reactions (including anaphylaxis), hyperbilirubinemia in neonates (especially with IV administration). ## Key Drug Interactions * **Warfarin and other Vitamin K antagonists:** Phytonadione reverses the anticoagulant effects of warfarin. Concurrent administration requires careful monitoring of INR. * **Orlistat:** May decrease absorption of fat-soluble vitamins, including Vitamin K1. * **Cholestyramine and Colestipol:** Bile acid sequestrants can interfere with the absorption of fat-soluble vitamins. * **Mineral Oil:** Can decrease absorption of fat-soluble vitamins. * **Antibiotics:** Long-term use of certain antibiotics can reduce gut flora necessary for Vitamin K synthesis. ## Monitoring * Prothrombin time (PT) and International Normalized Ratio (INR) in patients receiving anticoagulants or with suspected Vitamin K deficiency. * Signs of bleeding. ## Clinical Pearls * Vitamin K1 is fat-soluble; administration with food may enhance absorption for oral formulations. * Intramuscular injection is generally preferred over subcutaneous for consistency of absorption. * Intravenous phytonadione should be administered slowly and diluted to minimize the risk of anaphylactoid reactions. * Ensure adequate dietary intake of Vitamin K if deficiency is related to poor nutrition. *** **Disclaimer:** This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the most current prescribing information and institutional protocols for definitive guidance. Dosing and indications may vary based on patient-specific factors and local guidelines.